Clinical Trial

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center,open-label,single-dose clinical trial of anti-CD20/CD30-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after lymphocyte depletion pre-treatment. In this study phase,a traditional "3+3"trial design is employed for dose escalation.
Trial Details
NCT Number NCT06519344
Lead Sponsor Shanghai Tongji Hospital, Tongji University School of Medicine
Conditions B Cell Malignancies
Enrollment 12 participants
Start Date 2024-07-31
Primary Completion 2026-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-25